Nanolynx Biologics develops conditionally active nanobody-drug conjugates (CA-NDCs) that remain inert in healthy tissue and activate only within the acidic tumor microenvironment. Their IntelliBody™ platform uses generative AI trained on a proprietary dataset of 200 million datapoints to engineer pH-dependent binding for hard-to-treat solid tumors. The company targets validated antigens like CD70 and CD142, aiming to overcome the poor penetration and systemic toxicity that limit conventional ADCs.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional antibody-drug conjugates (ADCs), while clinically validated for certain cancers, face fundamental limitations in solid tumors: they are too large to penetrate dense tumor tissue effectively and cause severe off-target toxicity in healthy tissue. This narrow therapeutic window restricts dosing and limits efficacy for patients with hard-to-treat solid tumors.
Solution
Nanolynx Biologics develops conditionally active nanobody-drug conjugates (CA-NDCs) that are engineered to remain silent at physiological pH 7.4 and switch on only in the acidic tumor microenvironment. At roughly 10× smaller than antibodies, these conjugates achieve deep tumor penetration while sparing healthy tissue, thereby widening the therapeutic window. The IntelliBody™ platform leverages generative AI trained on an exclusively licensed dataset of 200 million nanobody-antigen interaction datapoints across 15 oncology targets to design pH-dependent binding with precision. Each new target validated through this modular platform adds a revenue stream without requiring a rebuild of the underlying engine, enabling scalable expansion across a pipeline of clinically validated antigens.
Target Audience
Primary customers are oncology-focused biopharmaceutical companies and clinical research organizations developing treatments for solid tumors with high unmet medical need, particularly those seeking alternatives to conventional ADCs with improved safety and efficacy profiles.
Features
- IntelliBody™ platform uses generative AI trained on a proprietary, exclusive dataset of 200 million datapoints across 15 oncology targets to engineer pH-dependent binding
- CA-NDCs are ~10× smaller than conventional antibodies, enabling deep solid-tumor penetration
- pH-sensitive conditional activation ensures the drug is inactive at pH 7.4 in healthy tissue and fully active in the acidic tumor microenvironment, reducing systemic toxicity
- Targets clinically validated antigens (CD70, CD142) with proven links to approved drugs, yet constrained by ADC toxicity—the exact gap CA-NDCs address
- Modular platform architecture allows standardized campaigns for scalable expansion into new oncology targets